Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Published:2019-02 Issue:2 Volume:9 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Stewart A. Keith,Krishnan Amrita Y.,Singhal Seema,Boccia Ralph V.,Patel Manish R.,Niesvizky Ruben,Chanan-Khan Asher A.,Ailawadhi Sikander,Brumm Jochen,Mundt Kirsten E.,Hong Kyu,McBride Jacqueline,Shon-Nguyen Quyen,Xiao Yuanyuan,Ramakrishnan Vanitha,Polson Andrew G.,Samineni Divya,Leipold Douglas,Humke Eric W.,McClellan James Scott,Berdeja Jesus G.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-019-0178-8.pdf

Reference31 articles.

1. Pianko, M. J., Liu, Y., Bagchi, S. & Lesokhin, A. M. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig. 4, 32 (2017).

2. Zhang, T. et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Oncotarget 8, 34001–34017 (2017).

3. Chhabra, S. Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics. Pharmaceuticals 10, https://doi.org/10.3390/ph10020040 (2017).

4. Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311–1320 (2017).

5. Capone, M., Bryant, J. M., Sutkowski, N. & Haque, A. Fc receptor-like proteins in pathophysiology of B-cell disorder. J Clin Cell Immunol. 7, https://doi.org/10.4172/2155-9899.1000427 (2016).

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

4. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma;Current Hematologic Malignancy Reports;2024-08-15

5. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04